TASLY(SH:600535) Shang Hai Zheng Quan Bao·2026-02-06 19:31Group 1 - The company, Tianjin Tasly Pharmaceutical Co., Ltd., has signed a termination agreement with Arbor Pharmaceuticals, LLC, due to Arbor's acquisition by Azurity Pharmaceuticals, Inc. The termination was mutually agreed upon after discussions between both parties [2][4]. - The company received a total of $7.5 million as part of the termination agreement, which includes milestone payments and commercialization royalties related to the T89 product in the U.S. market [2][6]. - The termination of the agreement will not have a significant impact on the company's project advancement, production operations, or financial status. The company will continue to manage the termination-related matters appropriately [6]. Group 2 - In 2025, the company officially became part of China Resources Sanjiu, completing a "100-day integration" and steadily promoting the "first-year integration" efforts. The focus remains on stabilizing business, teams, and clients while enhancing efficiency and competitiveness [8]. - The company reported a total revenue of 8.236 billion yuan for 2025, a decrease of 3.08% year-on-year, while the net profit attributable to shareholders increased by 15.68% to 1.105 billion yuan. The decline in revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial income due to industry policy impacts [8].